Irradiation, Preclinical Imaging, & Microscopy (IPIM)

项目摘要/摘要：辐射、临床前成像和显微技术 放射、临床前成像和显微镜共享资源(IPIM)提供全面的阵列 先进的癌症相关诊断成像和治疗仪器/细胞技术， 组织，以及大小动物，重点放在临床前工作，为随后的快速 临床翻译。辐射服务配备了用于细胞和动物的137Cs辐照器。光学 细胞成像和电子显微镜提供多种类型的共聚焦、TIRF和广域荧光 显微镜成像，以及扫描和透射式电子显微镜。啮齿动物成像组件 包括PET、CT、MRI、生物发光/荧光(Xenogen/IVIS)和Visualsonics Vevo 770 High- 频率超声波。大型动物成像包括MRI、fMRI、CT、PET、超声波、荧光透视/ 作为独一无二的外科创新中心(CSI)的一部分，我们提供了血管成像、术中MRI/CT等技术。因为它的 在当前的资助期间，CSI总共支持了7项同行评议的研究资助，其中5项 他们来自NCI。值得注意的CSI项目包括人-猪的开发、成像和治疗 异种移植脑瘤模型及头颈部MRI兼容器械的研制 在核磁共振中术中环境下进行的癌症手术，以及新术中环境的开发 神经显像剂。CSI的功能目前只在几个最大的临床中可用 IPIM的独特之处在于具有用于大型动物研究的类似能力。自.以来 2015年，来自所有4个NCCC研究计划的55个NCCC成员使用了IPIM设施(CPS[2]， CBT[22]、ICI[16]、TEC[15])。NCCC资助的会员用户占总用户的72%，我们要求 仅有20%的IPIM总预算来自CCSG资金。NCCC成员支持的项目的例子包括 双模式/双代理成像(Davis、Pogue和Samkoe[TEC])，相关的基本机制 通过膜交通控制微血管通透性、血管生成和推动肿瘤的炎症 血管系统和后续治疗(Stan、Turk、Fiering、Noelle[ICI]和Pogue[TEC])；以及Cherenkov 辐射作为放射肿瘤学环境中的实时剂量测定工具(Pogue、Gladstone、Hoope和 贾维斯[TEC])。除了提供出色的可行成像外，IPIM还将专注于精确组合/联合 将广泛的放射成像技术与活细胞成像、分子靶向 以及将引领下一代诊断和治疗的遗传学。该资源配备了人员 由高素质的研究总监和经验丰富的资源经理维护工具， 提供技术支持，培训NCCC研究人员，并帮助升级IPIM技术。 最近的改进包括升级NCCC小动物9.4T磁共振成像。有待改进的地方 包括更换我们小动物CT和全动物IVIS荧光/生物发光成像仪 致力于将解剖成像参数与分子组织病理学和遗传学共同注册。

Project Summary/Abstract: Irradiation, Preclinical Imaging, and Microscopy The Irradiation, Preclinical Imaging, and Microscopy Shared Resource (IPIM) provides a comprehensive array of sophisticated cancer relevant diagnostic imaging and therapeutic instrumentation/techniques for cells, tissues, and large and small animals, with a focus on preclinical work that sets the stage for subsequent rapid clinical translation. Irradiation services are provided with a 137Cs irradiator for use on cells and animals. Optical cellular imaging and electron microscopy provides multiple types of confocal, TIRF and wide-field fluorescence microscopy imaging, as well as scanning and transmission electron microscopy. Rodent imaging components include PET, CT, MRI, Bioluminescence/Fluorescent (Xenogen/IVIS), and VisualSonics Vevo 770 high- frequency ultrasound. Large animal imaging includes MRI, fMRI, CT, PET, ultrasound, fluoroscopy/ angiography, and intra-operative MRI/CT as part of the unique Center for Surgical Innovation (CSI). Since its opening during the current funding period, CSI has enabled a total of 7 peer-reviewed research grants, 5 of which are from NCI. Notable CSI projects include development, imaging, and treatment of a human-porcine xenograft brain tumor model, development of MRI-compatible instrumentation for facilitation of head and neck cancer surgeries performed in the MRI-intraoperative environment, and development of a novel intraoperative nerve imaging agent. The capabilities of the CSI are currently available in only a few of the largest clinical research institutions, and IPIM is distinct in having similar capabilities for use in large animal studies. Since 2015, IPIM facilities have been utilized by 55 NCCC Members from all 4 NCCC Research Programs (CPS [2], CBT [22], ICI [16], TEC [15]). NCCC Funded Member Users represented 72% of Total Users, and we request only 20% of Total IPIM budget from CCSG funding. Examples of NCCC Member-supported projects include dual modality/dual agent imaging (Davis, Pogue and Samkoe [TEC]), fundamental mechanisms associated with membrane traffic control microvascular permeability, angiogenesis and inflammation that drive tumor vasculature and subsequent treatment (Stan, Turk, Fiering, Noelle [ICI] and Pogue [TEC]); and Cherenkov irradiation as a real-time dosimetry tool in the radiation oncology setting (Pogue, Gladstone, Hoopes, and Jarvis [TEC]). In addition to providing outstanding viable imaging, IPIM will focus on accurately combining / co- registering the extensive array of radiological imaging techniques with live cell imaging, molecular targeting and genetics that will lead the way into the next generation of diagnosis and therapy. The resource is staffed by highly qualified research directors and experienced resource managers that maintain instrumentation, provide technical support, educate NCCC researchers, and are instrumental in upgrading IPIM technologies. Recent enhancements have included upgrading of the NCCC small animal 9.4T MRI. Pending improvements include replacement of our small animal CT and whole animal IVIS fluorescent/bioluminescent imagers and a dedicated effort to co-register anatomic imaging parameters with molecular histopathology and genetics.